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Salmonella enterica serovar Paratyphi A is increasing-
ly a cause of enteric fever. Sequence analysis of an Indian
isolate showed a unique strain with high-level resistance to
ciprofloxacin associated with double mutations in the DNA
gyrase subunit gyrA (Ser83→Phe and Asp87→Gly) and a
mutation in topoisomerase IV subunit parC (Ser80→Arg).
S
almonella enterica serovar Paratyphi A is the second
most common cause of enteric fever after S. Typhi.
Approximately 0.25 S. Paratyphi Ainfections (paratyphoid
fever) occur for each S. Typhi infection (typhoid fever) (1).
Given global estimates of >21 million cases of typhoid
fever in the year 2000, >5 million cases per year of S.
Paratyphi A probably occur. Paratyphoid fever is a major
clinical problem in India, but large outbreaks were not
reported until 1996 (2). Elsewhere, in southern China for
example, extensive outbreaks are also occurring (3). 
Since 1998, plasmid-mediated multidrug resistance in
S. Paratyphi A, associated with chromosomally mediated
reduced susceptibility to ciprofloxacin, has caused concern
(4). Reduced susceptibility to fluoroquinolones results in a
poor response of salmonellosis patients to treatment and
may allow prolonged bacterial shedding (5). Rising resist-
ance to fluoroquinolones is likely to be driving an increase
in cases of paratyphoid fever in regions where fluoro-
quinolones are used empirically to treat enteric fever. We
must monitor the emergence of resistance in this enteric
pathogen to differentiate between the acquisition of resist-
ance during treatment (mutations occurring in different
bacterial strains) or clonal expansion of a successful strain
by person-to-person spread (identical mutations associated
with a single strain). To do so, we need to describe the
molecular basis of resistance and the genotype of the
resistant strains. High-level ciprofloxacin-resistant S.
Paratyphi A (MIC 8 µg/mL) is present in India (6) and
Japan (MIC >128 µg/mL) (7). However, because S. Typhi,
the major cause of enteric fever in India, has not yet devel-
oped high-level resistance to fluoroquinolones, enteric
fevers are often treated empirically with fluoroquinolones.
If this trend continues, fluoroquinolone-resistant strains of
S. Paratyphi A are almost certain to become a major cause
of enteric fever in many areas. 
We analyzed, by DNAsequencing, the DNAgyrase and
topoisomerase IV genes of the first reported highly fluoro-
quinolone-resistant S. Paratyphi Aisolate (6). We looked at
the full coding sequence, including the quinolone resist-
ance–determining region (QRDR), of both subunits of
DNA gyrase and topoisomerase IV for mutations associat-
ed with resistance to fluoroquinolones. We also used mul-
tilocus sequence typing (MLST) to confirm the identity of
the isolate.
The Study
The strain described here (Pond1) was first isolated in
Pondicherry, India, in November 2002 from the blood of a
23-year-old man admitted with fever and with no history
of having received antimicrobial chemotherapy (6). The
isolate was resistant to ciprofloxacin and nalidixic acid,
and the MIC of ciprofloxacin was 8 mg/L. It was sensitive
to all other antimicrobial drugs tested by disk diffusion:
ampicillin, chloramphenicol, cotrimoxazole, gentamicin,
and ceftriaxone. Repeat testing showed that zones of inhi-
bition indicating susceptibility were seen around both
ofloxacin (17 mm) and ciprofloxacin (21 mm) 5-µg disks;
however, in light of the ciprofloxacin MIC and resistance
to nalidixic acid, Pond1 was considered resistant to fluoro-
quinolones. No similar isolates have been seen in this area
since the initial report, although the total number of paraty-
phoid fever cases has increased.
Polymerase chain reaction (PCR) amplification (Table 1)
and direct DNA sequencing of both strands of the full
length of gyrase (gyrA and gyrB) and topoisomerase IV
(parC and parE) subunit genes was performed with an ABI
Prism dye terminator cycle sequencing kit (Perkin Elmer,
Foster City, CA, USA) on an ABI 3730 automated
sequencer. Results showed 3 mutations: 2 in gyrA and 1 in
parC. A comparison of these mutations with those previ-
ously described in fluoroquinolone-resistant S. Paratyphi A
is shown in Table 2. A rise of fluoroquinolone resistance
over time is apparent, and although the point mutations do
not fully explain the MIC data, we noted general associa-
tions: a single mutation in gyrA is always associated with
resistance to nalidixic acid and reduced susceptibility to
ciprofloxacin and ofloxacin, and a double mutation in gyrA
is always accompanied by mutations in parC and is asso-
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sample is limited, heterogeneity in mutations found at all
sites suggests that this finding is not the result of a single
successful strain’s sequentially acquiring mutations but
rather that resistance is arising in several different strains.
Conclusions
The QRDR within topoisomerases contains hotspots
for mutations around the active site, which are associated
with raised MIC values for fluoroquinolones (10). For
gyrA from nalidixic acid–resistant Salmonella isolates, 2
mutations are most frequently observed in clinical isolates:
Ser83→Phe and Ser83→Tyr (8,9,11). The association with
resistance of mutations seen in parC, however, is less clear
(12). Mutations in parC of gram-negative bacteria are usu-
ally within the QRDR at amino acids 80 and 84 (Ser
80→Ile, Glu 84→Gly, Lys). The first reported mutation
was Thr57→Ser, and other mutations have been described:
Asp 79→Ala, Gly 78→Asp (9). Each mutation, in gyrA or
parC, can give rise to different MICs in different isolates,
which means that other factors must also influence the
resistance phenotype in S. Paratyphi A. The most likely
cause is changes in expression levels of proteins involved
with permeability barriers and efflux pumps. These
changes could be the result of either point mutations in
transcription promoters and regulators or downstream
effects of mutations in topoisomerases. Known mecha-
nisms of fluoroquinolone resistance that we were able to
screen for include transmissible plasmidborne resistance
and efflux pumps. The qnr-containing plasmid was not
detected with PCR using primers 5′ GGG TAT GGA TAT
TAT TGA TAA 3′ and 5′ CTAATC CGG CAG CAC TAT
TA 3′ (13) in Pond1, and sensitivity testing gave the same
zone size around both tetracycline and chloramphenicol
discs when compared with a nalidixic acid–susceptible
isolate. This finding, combined with the ciprofloxacin MIC
of 8 µg/mL, argues against the presence of multiple
antimicrobial drug resistance efflux pumps. Thus the high-
level resistance seen in Pond1 appears to be associated
directly with 3 point mutations in the topoisomerase genes.
To confirm the identity of the isolate as S. Paratyphi A,
we used MLST. The primer sequences and MLST data are
available from the MLST database at the Max-Planck-
Institut für Infektionsbiologie (http://web.mpib-berlin.
mpg.de/mlst/). Six of 7 sequenced loci matched exactly the
previously described sequences, and 1 was a unique allele.
This finding means that the isolate described here is with-
in the clonal MLST group described as S. Paratyphi A but
is a recognizable variant. This finding supports previous
typing data that show very little variation (14); typing S.
Paratyphi A is problematic because genomic restriction
analyses (pulsed-field gel electrophoresis) of isolates from
an outbreak are not always identical, and susceptible and
resistant strains cannot be differentiated. For molecular
epidemiologic studies to be carried out, several methods
need to be used (15). A broader study of single base-pair
differences between strains of S. Paratyphi Acould provide
a usable typing scheme.
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itored because the acquisition of resistance to fluoro-
quinolones, coupled with the reduction in S. Typhi by the
use of typhoid-specific vaccination, may cause S.
Paratyphi A to become the main cause of enteric fever.
Disc susceptibility testing does not always detect resist-
ance, and screening with nalidixic acid and MIC testing
remains the method of choice. The isolate described here,
Pond1, contains a unique combination of mutations that
provides a way to track the spread of this strain of S.
Paratyphi A. 
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